Pyridoxine hydrochloride

ApprovedSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Pyridoxine hydrochloride is one of 136 small molecule programs targeting Peripheral Neuropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

135

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral NeuropathyActive, not recruiting

Pulmonary TuberculosisActive, not recruiting

ImmunodeficiencyActive, not recruiting

TuberculosisActive, not recruiting

Peripheral NeuropathyApproved

Active, not recruiting

Pulmonary TuberculosisPhase 1

Active, not recruiting

ImmunodeficiencyPreclinical

Active, not recruiting

TuberculosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

297 competitors in Tuberculosis

#DrugCompanyPhaseTrials

Lamprene

Novartis

Phase 3

5 2

Bayer Aspirin

Bayer

Phase 3

—3

TB Alliance

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

3 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

2 5

Pyridoxine hydrochloride

NNational Institute of Allergy and Infectious Diseases (NIAID)

Approved

2 6

Antiretroviral Medications

FFrench National Agency for Research on AIDS and Viral Hepatitis

Phase 3

1 7

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Preclinical

22 8

Tivicay

GSK

Preclinical

4 9

Biktarvy

Gilead

Preclinical

1 10

Cysteine Hydrochloride

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Children

NCT05994742

Clinical

Trials by Indication[1]

Active, not recruiting·QQueen Mary University of London·Phase 3·NCT05994742·674 enrolled

Peripheral Neuropathy1 trial

Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy

Completed·—·Phase 4·NCT02923388·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Pyridoxine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pyridoxine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pyridoxine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Pyridoxine hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Immunodeficiency3 trials

Pulmonary Tuberculosis2 trials

Tuberculosis2 trials

Children1 trial

Peripheral Neuropathy1 trial

References

Drug Info

Quick Facts

Related News